Reimbursed Care Access in Canada

Health Canada states there are no authorized therapeutic products containing psilocybin in Canada and that legal access is limited to defined regulatory pathways: clinical trials, the Special Access Program (SAP), or individual subsection 56(1) exemptions to the CDSA. Health Canada explicitly describes the SAP pathway and subsection 56(1) exemption route as the principal lawful ways a regulated health professional may obtain psilocybin for a patient when other options are unsuitable, and notes SAP requests are assessed case-by-case and require manufacturer/supplier assurances about quality (GMP) where possible. #

In practice this means psilocybin is not an approved, reimbursed pharmaceutical product on Canadian formularies; access that has occurred clinically has been through clinical trials, SAP letters of authorization, or limited subsection 56(1) exemptions (which allow specified activities in relation to an authorization). Health Canada advises practitioners to pursue clinical trials or SAP prior to considering individual exemptions and highlights practitioner reporting and oversight requirements for SAP-authorized use. Payment for any psilocybin administration outside of publicly funded trials or programs is therefore typically private (patient or private insurer), and provincial public drug programs have not broadly listed psilocybin for reimbursement. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Health Canada’s informational pages list MDMA (ecstasy) as illegal and note that therapeutic research is occurring in controlled clinical trial settings rather than via an approved marketed product or routine clinical prescription. #

(Research context) Canadian access for MDMA-assisted therapy has therefore been limited to investigational/clinical-trial frameworks or any ad hoc approvals that might be issued through Health Canada mechanisms; there is no general reimbursement or programmatic public coverage for MDMA-assisted treatment outside of funded trials. #

Esketamine (marketed as Spravato) is authorized in Canada as a nasal spray for certain adults with major depressive disorder (treatment-resistant or where urgent psychiatric care is required) under a Notice of Compliance with conditions; Health Canada product information and decision summaries describe the indication and controlled distribution requirements. The product monograph and Health Canada communications note Spravato’s use together with an oral antidepressant and emphasize controlled distribution, administration by a healthcare professional, and post-administration monitoring. # #

Reimbursement and coverage: Spravato’s availability in Canada has been subject to manufacturer market decisions and provincial formulary processes. CADTH has produced health-technology/rapid assessments noting cost and administration considerations, and some CADTH material observed the product was not widely marketed in Canada at the time of review and that provincial reimbursement decisions would vary; in short, Spravato’s administration requires specialized clinic setups and—where available—coverage is determined at provincial/territorial formulary and insurer levels rather than as a nationwide, universally reimbursed therapy. #

Operational implications: because Spravato is supplied under a controlled distribution program with monitoring requirements, treatment is ordinarily delivered in supervised clinical settings; patients should check provincial/territorial drug plan criteria and private insurer policies for potential coverage, which is variable and often limited to exceptional or case-by-case reimbursement.

Ketamine is an authorized anesthetic in Canada (e.g., Ketalar) and is listed as a controlled substance under Schedule I of the Controlled Drugs and Substances Act; Health Canada documents describe legitimate medical uses (anesthesia) while also noting risks and non-medical harms. #

Off-label psychiatric use: Intravenous or intramuscular ketamine is used off‑label in Canada by some clinicians for depression (including treatment‑resistant depression) and acute suicidality; such use is not an indicated, Health Canada‑approved psychiatric indication (unlike Spravato for esketamine). Off‑label ketamine administration for psychiatric indications is typically arranged through hospital or private clinics, billed privately or through institution-specific funding, and provincial public drug plans generally do not provide routine reimbursement for off‑label ketamine infusions for psychiatric indications. Health Canada’s safety communications and product monographs remain the reference for clinical risk mitigation when ketamine is used medically. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Health Canada treats DMT and DMT‑containing products as controlled substances; lawful access is limited to regulated clinical trials or case‑by‑case regulatory mechanisms. #

There is no marketed, reimbursed DMT product in Canada; any therapeutic use would be via clinical research or exceptional SAP/exemption pathways overseen by Health Canada. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 5‑MeO‑DMT is treated as an illicit/controlled hallucinogen under Health Canada guidance and is not an authorized therapeutic product; lawful clinical access is limited to approved research contexts or exceptional regulatory authorization. #

There is no public reimbursement framework or marketed therapeutic product for 5‑MeO‑DMT in Canada.

Currently classified as a prescription‑status substance on Health Canada’s Prescription Drug List (PDL) but is not an authorized therapeutic product for sale in Canada; Health Canada added ibogaine and its salts/derivatives to the Human and Veterinary Prescription Drug Lists and has issued risk communications about serious and fatal adverse reactions associated with its use. As such, ibogaine is not a marketed, reimbursed treatment and lawful access would be exceptional, restricted, or via clinical research. #

Because ibogaine is not authorized for clinical use in Canada and has reported serious safety signals, Health Canada explicitly advises against non‑regulated use; any therapeutic or research activity would require appropriate regulatory approvals and would not be covered routinely by public formularies.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Ayahuasca preparations contain DMT (a controlled substance) and therefore the preparation and use are illegal outside of authorized clinical research or any narrowly granted exemptions; Health Canada’s controlled drug materials cover DMT‑containing substances under the broader controlled/illegal drugs framework. # #

There is no authorized, reimbursed program for ayahuasca in Canada; access for therapeutic purposes would be limited to approved research or exceptionally granted regulatory exemptions.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (a naturally occurring phenethylamine found in peyote and other cacti) is controlled under the CDSA framework and is not an approved therapeutic product in Canada; lawful therapeutic access would be limited to clinical trials or exceptional authorization. #

There is no public reimbursement pathway or marketed mescaline therapeutic product in Canada.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. The 2C family (novel phenethylamines/2C‑series) are treated as controlled/illegal drugs and are not authorized therapeutic agents in Canada; access for research purposes requires appropriate regulatory approvals. #

There is no marketed or reimbursed 2C‑series product in Canada.